Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Emergent BioSolutions
< Previous
1
2
Next >
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
January 11, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
January 09, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
November 28, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
November 24, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
November 08, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
October 30, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
October 19, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
October 02, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
LQDA
Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
August 30, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Reports Financial Results for Second Quarter 2023
August 08, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
August 08, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
July 31, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
July 25, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
July 20, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Announces CEO Transition
June 27, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
May 15, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
May 11, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Reports Financial Results For First Quarter 2023
May 09, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
April 19, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
March 29, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
February 27, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use
February 15, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
February 15, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
BVNRY
EBS
Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
February 06, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus
January 09, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense
January 05, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray
December 06, 2022
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
November 14, 2022
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Reports Financial Results For Third Quarter 2022
November 08, 2022
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
November 01, 2022
From
Emergent BioSolutions
Via
GlobeNewswire
Tickers
EBS
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.